NAMS - NASDAQ

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMSยทNASDAQ

$32.11

+0.75%
HealthcareBiotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$3.75B
EPS-1.7500
P/E Ratio-18.35
Earnings Date08/05/2026
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. Fair Value Envelope

NAMS ยท NASDAQ

Our analysis suggests that NAMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.11, this represents a potential HIDDEN relative to our calculated worth for NewAmsterdam Pharma Company N.V..

HIDDEN
Intrinsic Value
Current Price: $32.11

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.4B
+ Cash & Equivalents$490.0M
Firm Value-$917.8M
- Debt$202.0K
Equity Value-$918.0M
/ Shares Outstanding116,903,979B
DCF Value-$8
OVERVALUED BY 124%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$158.2M
-$169.3M
-$181.2M
-$194.0M
-$207.6M
-$222.3M
-$237.9M
-$254.6M
-$272.6M
-$291.7M
Maintenance CapEx
-$52.7K
-$56.4K
-$60.3K
-$64.6K
-$69.1K
-$74.0K
-$79.2K
-$84.8K
-$90.7K
-$97.1K
Owner Earnings
-$158.2M
-$169.4M
-$181.3M
-$194.1M
-$207.7M
-$222.3M
-$238.0M
-$254.7M
-$272.7M
-$291.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$146.5M
-$145.2M
-$143.9M
-$142.6M
-$141.4M
-$140.1M
-$138.9M
-$137.6M
-$136.4M
-$135.2M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your NAMS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.